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DOI: 10.1039/b915928bPolymer–peptide conjugates are utilised to render small-molecule
inhibitors of the kinase IspE, a promising new antimalarial target,
water-soluble. It is shown that the peptide sequence of poly(ethylene
oxide)–peptide conjugates can be tailored to mediate specific inter-
actions with the ligands, allowing the solubilisation of even highly
challenging inhibitors. This strategy avoids compromising the
inhibitor structure to afford water solubility and potentially enables
the exploration of a greater structural space of both inhibitors and
drugs.Structure-based inhibitor design constitutes an attractive, alternative
approach to high-throughput screening. It has been successfully
applied to the development of efficient and selective inhibitors of
a number of drug targets such as BCR-Abl protein tyrosine kinase,
leading to gleevec used in the treatment of chronic myeloid leukemia.1
In addition to protein kinases, other kinases can also be interesting
drug targets. An example is the kinase IspE,2 an essential enzyme
involved in the biosynthesis of the universal isoprenoid precursors in
important pathogens3 and recognised target for the development of
drugs against infectious diseases such as malaria and tuberculosis.4
The ‘‘Lipinski rule of five’’5 empirically confines the space for drug-
like compounds to low-molecular-weight entities with rather lipo-
philic character. Active sites of enzymes are frequently embedded in
hydrophobic pockets of the protein, generating an environment
where specific polar interactions are highly prominent. During drug
development, an increase in affinity is often achieved with
a concomitant increase in hydrophobicity. The resulting highly
potent inhibitors often suffer from low water solubility, and can
therefore not be subject to in vitro assays. To overcome this difficulty,
several approaches have been explored to predict the water solubility
of drug candidates.6 These techniques include the utilisation of
numerical increments associated with known molecular fragments7 or
Monte Carlo simulations.8 Even if a reliable prediction can be found
to foresee the water solubility of potential inhibitors, a time-
consuming optimisation of the molecular structure is required.
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88 | Soft Matter, 2010, 6, 88–91formulation approaches using, for instance, solubilising agents such
as cyclodextrins,9 phospholipids10 or polymeric surfactants e.g. plur-
onics.11
Recent advances in the field of polymer–peptide conjugates have
paved the way to specific materials-science applications.12 It was
demonstrated that the peptide sequence in such bioconjugates can act
as a monodisperse functional segment, displaying specific interactions
programmed into the amino-acid sequence. This was exploited to (i)
programme microstructure formation, (ii) control biomineralisation
or silica morphogenesis, (iii) regulate the compactisation of plasmid
DNA or (iv) transport cytostatica to metastases in the lymphatic
system.13 If the interaction potential of peptide segments in polymer–
peptide conjugates can be fine-tuned, the development of a generic
specific solubilisation strategy, in which the peptide mediates carrier–
drug interactions, can be envisaged.
Here, we present our initial investigation on the development of
specific solubilisers to render potent inhibitors of IspE water-soluble.
The approach presented exhibits clear advantages compared to
established strategies, where either poly(ethylene oxide) (PEO) is
simply added to often rather complex drug formulations or func-
tional PEO is covalently conjugated to the drug entity. While the
former approach suffers from dilution problems, the latter implies the
modification of the drug, generating a new chemical entity. This
however, needs to be subject to a new validation process. The strategy
proposed herein does not encounter similar problems as the drug is
not covalently modified. An additional benefit is the fact that only the
peptide sequence might have to be altered. This involves straight-
forward automated peptide synthesis, which can be considered as
much less expensive and faster than a classical, synthetic optimisation
cycle of the inhibitor.
The structure-based design of IspE inhibitors was aided by the
modelling programme MOLOC (cf. ESI†).15 A new class of bisub-
strate inhibitors was developed (Fig. 1, inhibitors I–II), targeting both
the substrate- and the ATP-binding pockets of the enzyme IspE with
the potential for higher selectivity and higher binding affinity
(cf. Fig. S1, ESI†).16 In addition, some previously designed small-
molecule inhibitors, which only occupy the substrate-binding pocket
of IspE kinase, were also included in this investigation (cf. Fig. 1,
inhibitors III–IV),17
Bisubstrate inhibitors I and II were entirely insoluble under the
enzymatic assay conditions, whereas the monosubstrate inhibitors III
and IV were poorly soluble, yet their IC50 values
18 could be deter-
mined.17 In these in vitro assays, the assistance of organic cosolvents
such as up to 10 vol% DMSO was required to afford sufficient ligand
solubility. This cosolvent-addition strategy proved to be unsuccessful
for the class of bisubstrate inhibitors I and II. Presumably, the general
solubility issue can be ascribed to the cytosine moiety featured by all
derivatives.17b The remarkably low water solubility of the ligands I
and II in particular can be ascribed to the rigid structure andThis journal is ª The Royal Society of Chemistry 2010
Fig. 1 IspE inhibitors (left) and a library of polymer–peptide conjugates
screened to specifically solubilise the inhibitors (right) ordered by water
































































View Onlinepronounced hydrophobicity, as indicated by the high partition
coefficients (cf. clogD values provided in Fig. 1).
To overcome the solubility issues without an additional design
cycle and the coupled synthetic effort, de novo designed polymer–
peptide conjugates have been investigated to render inhibitors water-
soluble.
A total of five tailor-made peptide sequences were synthesised and
conjugated to PEO via an inverse conjugation approach (cf. Fig. 1,
polymers 1–5 and ESI†).19 The peptide sequences cover a broad
spectrum of polarity (from 1 which is rather nonpolar to 5 which is
highly polar) and differ in the hydrophobicity–hydrophilicity pattern.
As general design criteria, amino-acid residues were selected,
providing hydrophobic contacts [phenylalanine (Phe)], Coulombic
interactions [arginine (Arg) or aspartic acid (Asp)] and nonionic
hydrogen bonding [asparagine (Asn), serine (Ser) and threonine
(Thr)]. Sufficient conformational flexibility was ensured by glycine
(Gly) as spacer residue. Conceptionally, this allows to position
selective interaction capabilities along the peptide strand, assembling
a segment that modulates the interactions with the inhibitor entity.
The PEO block was selected to provide both water solubility and
shielding of the polymer–inhibitor complexes.
The solubilisation experiments were performed by dissolving one
equivalent of inhibitor and one to four equivalents of the polymeric
carrier in a small amount of DMSO. The resulting homogeneous
solution was diluted to 3.8 vol% DMSO by the addition of water with
a rate of 80 mL/h. A first screen of the monosubstrate inhibitors III
and IV with different carrier conjugates (1–5) indicated a straight-
forward solubilisation of the inhibitors by the most polar carrier 5
(cf. Table 1). This was to be expected due to the compact, polarThis journal is ª The Royal Society of Chemistry 2010nature of the inhibitors, in which the sulfonamide moiety participates
in extensive hydrogen-bonding interactions. It is noteworthy that the
overall content of DMSO could be reduced significantly from 10 to
1.3 vol% in the enzyme assay, if compared to the cosolvent strategy,
in which the polymeric carrier is absent. In all cases, the most polar
carrier 5, exhibiting a zwitterionic peptide, results in very successful
solubilisation (Table 1). However, inhibitor IV is also solubilised by
the rather apolar carriers 1 and 3. This reflects rather low specificity
for the class of monosubstrate inhibitors.
With this promising result in hand, the design of tailor-made
peptide sequences to afford carriers that would solubilise even the
most challenging bisubstrate inhibitors I and II was addressed
(Fig. 2a). To generate a sufficient interface between the carrier and the
inhibitors, peptide strands were composed in a straightforward
manner. Arg residues should serve to bind to the substituted
pyrimidine ring, which acts as cytosine analogue. The benzylic side
chain of the aromatic amino acid Phe should establish p–p stacking
interactions with the alkyne linkers, and polar amino-acid residues
should satisfy the heteroatoms of the pyridine rings and the ether
linker. The peptide sequence of carrier 2 was not terminated with an
Arg residue as present in carrier 4 but with a peptide-nucleic-acid
(PNA) monomer hypothesised to form a Watson–Crick base pair
with the cytosine moiety. By analogy, the guanine-PNA monomer
might form hydrogen-bonding contacts to the cytosine analogue.
Besides considering these straightforward design principles, the
modelling software MOLOC15 was used to assist peptide design
(Fig. 2b). To model potential sequences, the equilibrated inhibitor
was set stationary while letting the peptide freely optimise around the
inhibitor. Considering hydrogen-bond acceptor and donor sites as
well as hydrophobic and hydrophilic regions, it was possible to
generate a peptide sequence (1) that should be complementary to
inhibitor I.
Solubilisation of the bisubstrate inhibitors by the set of PEO–
peptide conjugates was studied by adopting similar DMSO–water
dilution protocols as described for the monosubstrate inhibitors. The
results are summarised in Table 1. As expected, the solubilisation of
ligands I and II proved to be more challenging compared to the
monosubstrate inhibitors. The results are clearly sensitive to fine
differences in functionality and polarity patterns in the peptide
sequences. This suggests a higher selectivity of the interactions in
these polymer–inhibitor complexes. While inhibitor II could only be
solubilised as a solution exhibiting slight opaqueness, for I only one
positive hit was found. Despite the structural analogies between
ligands I and II, the former was solubilised by highly polar carriers
(4 and 5), whereas effective solubilisers for the latter could be found at
the other end of the polarity spectrum (1 and 3). Interestingly, carrier
1 that was based on simple computer-assisted design could indeed
effectively enhance the solubility of the bisubstrate inhibitor I.
However, careful studies are required to solidify the strategy. It
should be highlighted that the current picture of the inhibitor–carrier
complex is certainly idealised as suggested by the fact that stoichi-
ometry is important. While inhibitor I is solubilised as a slightly
opaque solution if one equivalent of 1 is provided, addition of four
equivalents of the carrier polymer leads to a clear solution.
The solutions of solubilised inhibitors were characterised by means
of UV-vis spectroscopy and dynamic light scattering. UV-vis spec-
troscopy confirmed the ease of solubilisation of the monosubstrate
inhibitors (III and IV). Assuming an extinction coefficient of the
inhibitors that is independent of the solvent (methanol and water), theSoft Matter, 2010, 6, 88–91 | 89
Table 1 Solubilisation experiments and in vitro evaluationa
Inhibitor
Polymer carrier IC50 [mM]
1 2 3 4 5 Without carrierc With carrierf
I ++bf b +   n.d. 8.7
II   +b +b n.d. n.d.
III     ++bf 79.0d n.d.e
IV ++  ++bf ++ 8.0 8.0
a Solubilisation: : solid precipitate; : slightly turbid; +: slightly opaque; ++: clear solution (conditions: formulation via dilution approach
(100% DMSO/ 3.8 vol% DMSO in water; 16 h, 25 C). b Concentrations of solubilised inhibitors in mg/mL: c[I/1]app. ¼ 0.36; c[II/4]app. ¼ 0.20;
c[II/5]app. ¼ 0.18; c[III/5]app. ¼ 0.08; c[IV/3]app. ¼ 0.39; n.d. not determined due to insolubility. c Cosolvent-assisted solubilisation. d For comparison:
30% inhibition at 34 mM. e 30% inhibition at 47 mM. f Samples used for the inhibition study.
Fig. 2 (a) Illustration of the concept applying PEO–peptide conjugates
as specific solubilisers to render inhibitors of IspE water-soluble. While
the peptide segment modulates interactions with the inhibitor, the PEO-
block provides water solubility (F1–4 indicate side-chain functionalities of
amino acids). (b) Low-level molecular simulation of the peptide–inhibitor
complex [I/1], showing a local minimum structure. Interactions are
mediated by Arg1 and Asn4 providing hydrogen-bonding interactions,
Phe6 giving hydrophobic contacts and Asp8 leading to ionic interactions
































































View Onlineapparent inhibitor concentration could be estimated. The
quantitative UV measurements provided c[III]app.¼ 0.08 mg/mL and
c[IV]app.¼ 0.39 mg/mL, which meet the expected concentration range
(c[III/5]th. ¼ 0.1 mg/mL and c[IV/3]th. ¼ 0.5 mg/mL, respectively).
The estimated values of the bisubstrate inhibitors have been slightly
lower with c[I]app. ¼ 0.36 mg/mL and c[II]app. ¼ 0.18–0.20 mg/mL
(c[I/1]th. ¼ 0.5 mg/mL and c[II/4]th. ¼ c[II/5]th. ¼ 0.25 mg/mL,
respectively). Light scattering with a Nicomp Particle Sizer shows
structures beyond the detection limit, suggesting that the dominating
structures are well below 10 nm. A more detailed investigation of the
kinetically controlled aggregates and in particular of the fine struc-
tures of the peptide–inhibitor contacts have to be performed by
advanced scattering and NMR experiments.90 | Soft Matter, 2010, 6, 88–91These results demonstrate that polymer–peptide conjugates can be
successfully used to improve the water solubility of drug-like
compounds. For this approach to be viable, it had to be demon-
strated that the polymer does not affect the biological activity of the
inhibitors. A series of initial control experiments demonstrated that
the carriers (1–5) do not display inhibitory activity.
The IC50 values of the carrier–inhibitor complexes were deter-
mined, employing the established photometric assay as indicated in
Table 1 (footnote f).20 The IC50 values of the solubilised mono-
substrate inhibitors III and IV are in the micromolar range and agree
well within the error of the assay with values obtained previously for
the isolated inhibitors.17 The latter values were determined in the
presence of 10 vol% of DMSO as an organic cosolvent to solubilise
the inhibitors. Use of PEO–peptide conjugates allowed to decrease
the amount of DMSO down to 1.3% in the enzyme assay.
The fact that the IC50 value of bisubstrate inhibitor I could be
determined for the first time, can be considered an achievement. The
inhibitory activity of 8.7 mM lies in the range of the most potent
monosubstrate inhibitors described to date. Given that the inhibitor
is far from being an optimised system, this initial result is very
promising and sets the stage for further design cycles. In the mean-
time, further optimisation of the carrier and the formulation proto-
cols are currently ongoing to address other promising mono- and
bisubstrate inhibitors with low or no water solubility, also in view of
extending the solubilisation strategy to enzyme–inhibitor co-crystal-
lisation studies.
In summary, the application of polymer–peptide conjugates as
selective solubilisers to render small-molecule inhibitors water-soluble
has been reported. The approach presented enables the solubilisation
of mono- and novel bisubstrate inhibitors for IspE, an essential
kinase in the non-mevalonate pathway of isoprenoid biosynthesis
and a recognised drug target in the fight against infectious diseases
such as malaria or tuberculosis. A set of PEO–peptide conjugates
were screened to solubilise four different kinase inhibitors that show
low to no water solubility. While the peptide segment in the conjugate
could be programmed to modulate specific interactions with the
inhibitors, the PEO segment provides the complexes with water
solubility. The polymer–peptide conjugates afford water-soluble
inhibitors without affecting the biological activity of the inhibitors
analysed in the context of this study. Besides enhanced practicality,
the new approach will enable the use of a larger variety of structures,
given that the design of potential inhibitors no longer has to be guided
by features known to afford water solubility but rather by promising
































































View Onlinecandidates toward highly hydrophobic compounds. Moreover,
advanced functions can be integrated into the carrier structure,
setting the stage for controlled release of the cargo or strategies that
allow the homing of the carrier to address certain tissues or cells in
a specific manner.Acknowledgements
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